Kineta Inc
NASDAQ:KA
Kineta Inc
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Seattle, Washington and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The firm's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. The company is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Seattle, Washington and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The firm's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. The company is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.
